Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06628921Recruiting

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

Role: collaborator

NCT06414044Active Not Recruiting

Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients

Role: collaborator

NCT06409832Recruiting

RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

Role: collaborator

NCT05903027Recruiting

Gepant treAtments: EffectIveNess and tolERability (GAINER)

Role: collaborator

NCT05903040Completed

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Role: collaborator

NCT06409845Recruiting

Effectiveness and Tolerability of Eptinezumab

Role: collaborator

All 6 trials loaded